A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Crutzen (1933–2021), Dutch chemist, winner of the 1995 Nobel Prize in Chemistry for work on atmospheric chemistry, especially in relation to ozone Ana Maria Cuervo (born 1966), Spanish-American physician, researcher, and cell biologist, best known for work on autophagy Marie Curie (1867–1934), Polish and French radiation physicist, discovered the elements radium and polonium, 1903 Nobel Prize in Physics, 1911 Nobel Prize in Chemistry Pierre Curie (1859–1906), French physicist and chemist, 1903 Nobel Prize in Physics for work on radioactivity Robert Curl (1933–2022), American chemist, winner of 1996 Nobel Prize in Chemistry for discovery of the fullerene class of materials Theodor Curtius (1857–1928), German chemist known for the Curtius rearrangement, and also discovery of diazoacetic acid, hydrazine and hydrazoic acid Anthony Czarnik (born 1957), American chemist and inventor known for work on fluorescent chemosensors Emil Czyrniański (1824–1888), Polish chemist, known for developing chemical nomenclature in Polish
The plantar fascia contributes to support of the arch of the foot by acting as a tie-rod, where it undergoes tension when the foot bears weight. One biomechanical model estimated it carries as much as 14% of the total load of the foot. In an experiment using cadavers, it was found that failure of the plantar fascia averaged at loads of 118±244 newtons (12 ± 25 kilograms-force; 27 ± 55 pounds-force). Failure most often occurred at the proximal attachment to the calcaneus, which is consistent with the usual location of symptoms (i.e., in plantar fasciitis). Complete rupture or surgical release of the plantar fascia leads to a decrease in arch stiffness and a significant collapse of the longitudinal arch of the foot. By modeling it was predicted such conditions would result in a 17% increase in vertical displacement and a 15% increase in horizontal elongation of the foot when it was loaded at 683 newtons (70 kgf; 154 lbf). Surgical release also significantly increases both stress in the plantar ligaments and plantar pressures under the metatarsal heads. Although most of the figures mentioned above are from either cadaver studies or investigations using models, they highlight the relatively large load the plantar fascia is subjected to while contributing to the structural integrity of the foot.
== History == DOM was the first psychedelic of the DOx series to be discovered. It was first synthesized by Alexander Shulgin at Dow Chemical Company in 1963, who had had his first psychedelic experience, with mescaline (3,4,5-trimethoxyphenethylamine), in 1960. Shulgin personally tried DOM on January 4, 1964 and discovered its psychedelic effects. 2,4,5-Trimethoxyamphetamine (TMA-2; "DOMeO") had been synthesized by Bruckner in 1933, but its psychedelic effects were not described until Shulgin tried the compound and reported its effects in the scientific literature in 1964. Prior to this, 3,4,5-trimethoxyamphetamine (TMA; α-methylmescaline) had been synthesized by Hey in 1947, being found by him to produce euphoria, and was described by Peretz and colleagues in 1955 as clearly producing psychedelic effects. Following his discovery of DOM, Shulgin developed DOET and found that at low doses it was a remarkable "psychic energizer" without producing psychedelic effects at these doses. Dow Chemical Company decided to move forward with clinical trials of DOET as a potential pharmaceutical drug for such purposes. Shulgin and Dow Chemical Company filed a patent for DOET in 1966, although it was not published until 1970. Dow Chemical Company tasked Solomon H. Snyder at Johns Hopkins University with clinically studying DOET. In April 1967, following the banning of LSD in California in 1966, DOM emerged as a street drug and legal LSD alternative with the name "STP" (allegedly short for "Serenity, Tranquility, and Peace") in the Haight-Ashbury district in San Francisco.
Early ancient Chinese history is largely legendary, consisting of mythical tales intertwined with sporadic annals written centuries to millennia later. Sima Qian's Records of the Grand Historian recorded a period following the Battle of Zhuolu, during the reign of successive generations of confederate overlords (Chinese: 共主) known as the Three Sovereigns and Five Emperors (c. 2852–2070 BCE), who, allegedly, were elected to power among the tribes. This is a period for which scant reliable archaeological evidence exists – these sovereigns are largely regarded as cultural heroes.
Sources: en.wikipedia.org
=== Chemical === Roentgenium is the ninth member of the 6d series of transition metals. Calculations on its ionization potentials and atomic and ionic radii are similar to that of its lighter homologue gold, thus implying that roentgenium's basic properties will resemble those of the other group 11 elements, copper, silver, and gold; however, it is also predicted to show several differences from its lighter homologues. Roentgenium is predicted to be a noble metal. The standard electrode potential of 1.9 V for the Rg3+/Rg couple is greater than that of 1.5 V for the Au3+/Au couple. Roentgenium's predicted first ionization energy of 1020 kJ/mol almost matches that of the noble gas radon at 1037 kJ/mol. Its predicted second ionization energy, 2070 kJ/mol, is almost the same as that of silver. Based on the most stable oxidation states of the lighter group 11 elements, roentgenium is predicted to show stable +5 and +3 oxidation states, with a less stable +1 state. The +3 state is predicted to be the most stable. Roentgenium(III) is expected to be of comparable reactivity to gold(III), but should be more stable and form a larger variety of compounds. Gold also forms a somewhat stable −1 state due to relativistic effects, and it has been suggested roentgenium may do so as well: nevertheless, the electron affinity of roentgenium is expected to be around 1.6 eV (150 kJ/mol), significantly lower than gold's value of 2.3 eV (220 kJ/mol), so roentgenides may not be stable or even possible.
Machine learning applications can be biased if they learn from biased data. The developers may not be aware that the bias exists. Discriminatory behaviour by some LLMs can be observed in their output. Bias can be introduced by the way training data is selected and by the way a model is deployed. If a biased algorithm is used to make decisions that can seriously harm people (as it can in medicine, finance, recruitment, housing or policing) then the algorithm may cause discrimination. The field of fairness studies how to prevent harms from algorithmic biases. On 28 June 2015, Google Photos's new image labelling feature mistakenly identified Jacky Alcine and a friend as "gorillas" because they were black. The system was trained on a dataset that contained very few images of black people, a problem called "sample size disparity". Google "fixed" this problem by preventing the system from labelling anything as a "gorilla". Eight years later, in 2023, Google Photos still could not identify a gorilla, and neither could similar products from Apple, Facebook, Microsoft and Amazon. COMPAS is a commercial program widely used by U.S. courts to assess the likelihood of a defendant becoming a recidivist. In 2016, Julia Angwin at ProPublica discovered that COMPAS exhibited racial bias, despite the fact that the program was not told the races of the defendants.
== Weapons == Someone hit by a shotgun will not fly backwards like it is often portrayed in movies, and the same is true for other handheld weapons. The momentum of the bullet is no higher than the recoil transmitted to the shooter, which is too little to cause any significant motion. Land mines explode immediately when stepped on. They are not armed when stepped on and then triggered by stepping off, as depicted in fictional portrayals where disarming the mine is a source of narrative.
=== Structure === The carotid sheath is a fibrous connective tissue formation surrounding several important structures of the neck. It is thicker around the arteries than around the vein, allowing the vein to expand. The three major fascial layers in the neck contribute to the carotid sheath: the investing fascia, the pretracheal fascia, and the prevertebral fascia. The carotid sheath has limited loose connective tissue.
The Lewis-acid-catalyzed cyanosilylation of aromatic aldehydes has also been carried out by Long and co-workers using a MOF of the formula Mn3[(Mn4Cl)3btt8(CH3OH)10]. This material contains a three-dimensional pore structure, with the pore diameter equaling 10 Å. In principle, either of the two types of Mn(II) sites could function as a catalyst. Noteworthy features of this catalyst are high conversion yields (for small substrates) and good substrate-size-selectivity, consistent with channellocalized catalysis.
Sources: en.wikipedia.org
== Health == Domestic kittens in developed societies are usually vaccinated against common illnesses from two to three months of age. The usual combination vaccination protects against feline viral rhinotracheitis (FVR), feline calicivirus (C), and feline panleukopenia (P). This FVRCP inoculation is usually given at eight, twelve, and sixteen weeks, and an inoculation against rabies may be given at sixteen weeks. Kittens are usually spayed or neutered at seven months of age, but kittens may be neutered as young as seven weeks (if large enough), especially in animal shelters. Such early neutering does not appear to have any long-term health risks for cats, and it may even be beneficial in male cats. Kittens are commonly given deworming treatments for roundworms from about four weeks.
However, benzodiazepines have been used clinically to manage the adverse psychological effects of psychedelics, for instance in clinical studies and in the emergency department. A clinical trial of psilocybin and midazolam coadministration found that midazolam clouded the effects of psilocybin and impaired memory of the experience. Benzodiazepines might interfere with the therapeutic effects of psychedelics, such as sustained antidepressant effects. Some serotonergic psychedelics, for instance dimethyltryptamine (DMT) and 5-MeO-DMT, are highly susceptible substrates for monoamine oxidase (MAO), specifically MAO-A, and hence can be greatly potentiated by monoamine oxidase inhibitors (MAOIs). An example of this is ayahuasca, in which plants containing both DMT and harmala alkaloids acting as MAOIs such as harmine and harmaline are combined. This allows DMT to become orally active and to have a much longer duration of action than usual. The 2C psychedelics, such as 2C-B, 2C-I, and 2C-E, are also substrates of both MAO-A and MAO-B, and may likewise be greatly potentiated by MAOIs. Examples of MAOIs that may potentiate psychedelics behaving as MAO-A and/or MAO-B substrates include phenelzine, tranylcypromine, isocarboxazid, moclobemide, and selegiline. Combination of MAO-substrate psychedelics with MAOIs can result in overdose and serious toxicity, including death. Other psychedelics, such as LSD, are not substrates of MAO and are not potentiated by MAOIs.
Reptilian skin is covered in a horny cornified epidermis, making it watertight and enabling reptiles to live on dry land, in contrast to amphibians. Compared to mammalian skin, that of reptiles is rather thin and lacks the thick dermal layer that produces leather in mammals. The scaly skin typical of reptiles was likely inherited from the mutual common ancestor of amniotes, as early synapsids (as well as close relatives of amniotes like diadectomorphs) also had scaly reptile-like skin. This epidermis has differentiated alpha- and beta-keratin layers. Reptile skin varies from being highly pliable (snakes, geckoes) to inflexible (crocodilians, many turtles, many lepidosaurs) and the scales from highly overlapping (skinks and snakes) to having very little overlap (crocodilians, geckoes and agamids). Some areas of the body may not covered in scales (such as large areas of the body in turtles), but still generally have a rough appearance. Large plate-like scales, such as those covering the shells of turtles and the bodies of crocodilians, are referred to as scutes. The tips of reptile digits are generally capped with hard, curved cornified claws.
A synergy of two mechanisms, stabilization of closed conformation and exclusion of catalytic water by the tightly juxtaposed GAMEN loop was proposed as the mechanism of inhibition. Moreover, M1 aminopeptidases use a tyrosine residue in the active site to stabilize the transition state. In the case of IRAP, the catalytic Tyr549 is found in different orientations in the open and closed conformations. For example, in the case of phosphinic pseudopeptide inhibitors, which mimic the transition state of peptide substrates, Tyr549 changes orientation upon ligand binding to interact with one of the oxygen atoms of the phosphinic group, which is equivalent to the oxygen atoms of the substrate in the transition state.
When a beer has been brewed using a cool fermentation of around 10 °C (50 °F), compared to typical warm fermentation temperatures of 18 °C (64 °F), then stored (or lagered) for typically several weeks (or months) at temperatures close to freezing point, it is termed a "lager". During the lagering or storage phase several flavour components developed during fermentation dissipate, resulting in a "cleaner" flavour. Though it is the slow, cool fermentation and cold conditioning (or lagering) that defines the character of lager, the main technical difference is with the yeast generally used, which is Saccharomyces pastorianus. Technical differences include the ability of lager yeast to metabolise melibiose, and the tendency to settle at the bottom of the fermenter (though ale yeasts can also become bottom settling by selection); though these technical differences are not considered by scientists to be influential in the character or flavour of the finished beer, brewers feel otherwise – sometimes cultivating their own yeast strains which may suit their brewing equipment or for a particular purpose, such as brewing beers with a high abv.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.